이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

FARAPULSE 펄스장 절제 시스템을 사용하여 승모판 카테터 절제술을 포함한 지속성 심방세동의 반복 절제술 (ReMATCH)

2026년 10월 21일 업데이트: Boston Scientific Corporation

ReMATCH 연구는 FARAWAVE 및 FARAPOINT PFA 카테터를 포함한 FARAPULSE PFA 시스템을 활용하는 전향적, 단일 팔, 오픈 라벨, 다기관 연구입니다.

The ReMATCH Study is a prospective, single arm, open label, multi-center, study utilizing the FARAPULSE PFA System, including the FARAWAVE and FARAPOINT PFA Catheters.

연구 개요

상태

모집하지 않고 적극적으로

정황

개입 / 치료

상세 설명

The goal of this study is to evaluate the safety and effectiveness of using the FARAWAVE™ and FARAPOINT™ pulsed field ablation (PFA) catheters for re-treatment of persistent atrial fibrillation (PersAF) after a failed initial procedure.

연구 유형

중재적

등록 (추정된)

376

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

  • 대만
      • Taipei, 대만
        • National Taiwan University Hospital
      • Taipei, 대만
        • Taipei Veterans General Hospital
  • 미국
    • Alabama
      • Mobile, Alabama, 미국, 36607
        • Mobile Infirmary Medical Center
    • Arkansas
      • Jonesboro, Arkansas, 미국, 72401
        • Arrhythmia Research Group-Research Facility
    • California
      • Los Angeles, California, 미국, 90033
        • University of Southern California Hospital
      • Oxnard, California, 미국, 93030
        • St. John's Regional Medical Center
      • Stanford, California, 미국, 94305
        • Stanford University Medical Center
    • Colorado
      • Littleton, Colorado, 미국, 80120
        • South Denver Cardiology Associates, PC
    • Florida
      • Miami, Florida, 미국, 33133
        • HCA Florida Mercy Hospital
      • Naples, Florida, 미국, 34102
        • Naples Comprehensive Health
      • Orlando, Florida, 미국, 32803
        • AdventHealth Orlando-Hospital
      • Tampa, Florida, 미국, 33606
        • Tampa General Hospital
      • Tampa, Florida, 미국, 33613
        • AdventHealth Tampa-Hospital
    • Georgia
      • Atlanta, Georgia, 미국, 30322
        • Emory University Hospital
      • Macon, Georgia, 미국, 32201
        • Atrium Health Navicent The Medical Center
      • Savannah, Georgia, 미국, 31404
        • Memorial Health University Medical Center
    • Idaho
      • Boise, Idaho, 미국, 83712
        • St. Luke's Boise Medical Center
    • Illinois
      • Oak Lawn, Illinois, 미국, 60453
        • Advocate Christ Medical Center-Hospital
    • Maryland
      • Baltimore, Maryland, 미국, 21287
        • Johns Hopkins Hospital
    • Massachusetts
      • Boston, Massachusetts, 미국, 02114
        • Massachusetts General Hospital
      • Fall River, Massachusetts, 미국, 02720
        • Southcoast Physicians Group
    • Michigan
      • Royal Oak, Michigan, 미국, 48073
        • William Beaumont Hospital-Hospital
    • New Hampshire
      • Lebanon, New Hampshire, 미국, 03756
        • Dartmouth Hitchcock Medical Center
    • New Jersey
      • Marlton, New Jersey, 미국, 08053
        • Virtua Health Inc.
    • New Mexico
      • Albuquerque, New Mexico, 미국, 87102
        • Lovelace Medical Center
    • New York
      • Manhasset, New York, 미국, 11030
        • Northwell Health
      • New York, New York, 미국, 10065
        • Weill Cornell Medical University
    • Ohio
      • Cincinnati, Ohio, 미국, 45242
        • Bethesda North Hospital
      • Columbus, Ohio, 미국, 43210
        • Ohio State University Medical Center
    • Oklahoma
      • Tulsa, Oklahoma, 미국, 74104
        • Oklahoma Heart Institute
    • South Carolina
      • Charleston, South Carolina, 미국, 29406
        • Trident Medical Center
    • Texas
      • Austin, Texas, 미국, 78705
        • Texas Cardiac Arrhythmia Research
      • Tyler, Texas, 미국, 75701
        • Christus Trinity Mother Frances Health System
    • Utah
      • Salt Lake City, Utah, 미국, 84124
        • St. Mark's Hospital
    • Virginia
      • Norfolk, Virginia, 미국, 23507
        • Sentara Norfolk General Hospital
  • 호주
      • Melbourne, 호주
        • The Alfred Hospital
    • New South Wales
      • New Lambton Heights, New South Wales, 호주, 606-8507
        • John Hunter Hospital
      • Westmead, New South Wales, 호주, 2145
        • Westmead Hospital
    • Queensland
      • Brisbane, Queensland, 호주, 4001
        • St. Andrew's War Memorial Hospital
    • Victoria
      • Clayton, Victoria, 호주, 3168
        • Victorian Heart Hospital
      • Parkville, Victoria, 호주, 3050
        • The Royal Melbourne Hospital

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • ≥ 18 years of age, or older if required by local law
  • Single previous endocardial AF ablation procedure for PAF or PersAF that minimally included pulmonary vein isolation
  • Documented (physician's note) diagnosis of PersAF either prior to the subject's Index Procedure OR development of PersAF after the Index Procedure.
  • Documented evidence of symptomatic AF recurrence at least 60 days after the subject's Index Procedure, captured by any regulatory cleared rhythm monitoring device.

OR

  • If diagnosed with PersAF prior to the Index Procedure, documented recurrence of symptomatic AF or atypical AFL at least 60 days after the Index Procedure, captured by any regulatory cleared rhythm monitoring device.
  • Willing and capable of providing informed consent
  • Willing and capable of participating in all follow-up assessments and testing associated with this clinical investigation at an approved clinical investigational center

Exclusion Criteria:

  1. Atrial exclusions - Any of the following atrial conditions:

    a. Left atrial anteroposterior diameter ≥ 5.5 cm, or if LA diameter not available, non-indexed volume >100 ml (physician note or imaging) b. Current atrial myxoma c. Any PV abnormality, stenosis, or stenting (common and middle PVs are admissible) d. Current left atrial thrombus

  2. Cardiovascular exclusions - Any of the following CV conditions:

    1. History of sustained ventricular tachycardia or any ventricular fibrillation

    2. AF that is secondary to electrolyte imbalance, thyroid disease, alcohol, or other reversible / non-cardiac causes

    3. Current or anticipated implantable cardioverter defibrillator, cardiac resynchronization therapy devices, or implantable loop recorders, other than LUX-Dx. Patients with a pacemaker are permitted; however, pacemaker-dependent patients are excluded.

      Prior interatrial baffle, atrial septal patch, atrial septal defect closure device, patent foramen ovale occluder Left atrial appendage closure devices are excluded, with the exception of WATCHMAN. WATCHMAN is excluded if implanted within 90 days of enrollment

    4. Presence of any of the following:

      • Any prosthetic heart valve, ring or repair

      • Moderate to severe mitral valve stenosis

      • More than moderate mitral regurgitation (>3+)

      • Moderate to severe aortic stenosis

    5. Hypertrophic cardiomyopathy

    6. Any IVC filter, known inability to obtain vascular access or other contraindication to femoral access

    7. Awaiting cardiac transplantation or other cardiac surgery within the next 12 months

    8. Severe right ventricular dysfunction with documented echocardiography and/or hemodynamic data.

  3. Any of the following conditions at baseline:

    1. Heart failure associated with NYHA Class III or IV
    2. Documented LVEF < 40% as documented within the previous 12 months
    3. Uncontrolled hypertension (SBP > 160 mmHg or DBP > 95 mmHg on two (2) BP measurements at baseline assessment not attributable to white coat syndrome per Investigator opinion
    4. Body Mass Index (BMI) >45.0
    5. CHA2DS2-VASc score ≥5

  4. Any of the following events within 90 Days of the Consent Date:

    1. Coronary disease: Myocardial infarction (MI), unstable or Prinzmetal angina or coronary intervention within 90 days of consent or any documented history of severe non-revascularize coronary disease
    2. Cardiac surgery: Any cardiac surgery
    3. Heart failure hospitalization: Heart failure hospitalization
    4. Pericardium: Pericarditis or symptomatic pericardial effusion
    5. GI bleeding: Gastrointestinal bleeding
    6. Neurovascular event: Stroke, TIA, or intracranial bleeding
    7. Thromboembolism: Any active non-neurologic thrombus and/or thromboembolic event
    8. Carotid intervention: Carotid stenting or endarterectomy
    9. Diabetes: Uncontrolled diabetes mellitus or a recorded HgbA1c > 8.0%

  5. Any of the following congenital conditions:

    1. Congenital heart disease: Congenital heart disease with any clinically significant residual anatomic or conduction abnormality
    2. Methemoglobinemia: History of known congenital methemoglobinemia
    3. G6PD deficiency: History of known G6PD deficiency

  6. Any of the following conditions:

    1. Transplantation: Solid organ or hematologic transplant, or currently being evaluated for a transplant
    2. Diaphragmatic abnormality: Any prior history or current evidence of hemi-diaphragmatic paralysis or paresis.

    Pulmonary: Severe lung disease, severe pulmonary hypertension, or any lung disease involving abnormal blood gases or requiring supplemental oxygen d. Renal: Renal insufficiency if an estimated glomerular filtration rate (eGFR) is < 30 mL / min / 1.73 m2, or with any history of renal dialysis or renal transplant e. Malignancy: Active malignancy (other than squamous cell carcinoma) f. Gastrointestinal: Clinically significant gastrointestinal problems involving the esophagus or stomach including severe or erosive esophagitis, uncontrolled gastric reflux, gastroparesis, esophageal candidiasis or active gastroduodenal ulceration g. Infections: Active systemic infection h. Required use of phosphodiesterase inhibitors within 24 hours of the ablation procedure i. Nitroglycerin intolerance: Known allergic drug reaction to nitroglycerin (excluding hypotension) j. Hematologic condition: Known coagulopathy or bleeding disorder (e.g. von Willebrand disease, hemophilia) k. Contraindication to anticoagulation: Contraindication to, or unwillingness to use, systemic anticoagulation, or acceptable alternatives, pre-, intra- and post-procedure to achieve adequate anticoagulation.

    l. Pregnancy: Women of childbearing potential who are pregnant, lactating, not using medical birth control or who are planning to become pregnant during the anticipated study period m. General health conditions: Health conditions that, in the investigator's medical opinion, would prevent participation in the study, interfere with assessment or therapy, significantly raise the risk of study participation, or modify outcome data or its interpretation.

    n. LUX-Dx ICM intolerance: Unwillingness to receive, or unable to tolerate, a subcutaneous, chronically inserted LUX-Dx ICM device o. Participation in another trial: Subjects who are currently enrolled in another investigational study or registry that would directly interfere with the current study, except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments; each instance must be brought to the attention of the Sponsor to determine eligibility.

    p. Life expectancy: Predicted life expectancy less than one (1) year

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
다른: Single Arm Prospective

Repeat Ablation of Persistent Atrial Fibrillation, including Mitral Isthmus Catheter Ablation, with the FARAPULSE Pulsed Field Ablation System.
장치: FARAPULSE™ Pulsed Field Ablation System

The FARAPULSE™ Pulsed Field Ablation System is indicated for the treatment of symptomatic atrial fibrillation.

The FARAWAVE Catheter is indicated for the isolation of pulmonary veins and posterior wall in the treatment of drug-refractory, recurrent, symptomatic paroxysmal and persistent atrial fibrillation. The FARAWAVE Catheter is also indicated for the for the isolation of pulmonary veins and posterior wall in the treatment of persistent atrial fibrillation as an alternative to anti-arrhythmic drug (AAD) therapy as an initial rhythm control strategy.

The FARAPOINT™ PFA Catheter is indicated for use as an adjunctive device for 1) the creation of an ablation line between the inferior vena cava and the tricuspid valve and/or 2) Mitral Isthmus, when the FARAWAVE Catheter is used in the endocardial treatment of persistent atrial fibrillation (episode duration no greater than 12 months).

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Primary safety endpoint rate
기간: 60 days

The primary safety endpoint (PSE) is the proportion of Treatment subjects with one or more device or procedure-related Composite Serious Adverse Events (CSAEs) following the Repeat Ablation Procedure.
60 days
The primary effectiveness endpoint is the proportion of Treatment subjects with Acute Procedural Success.
기간: 24 hours

The proportion of Treatment Subjects with confirmed electrical block across all anatomical locations ablated with the investigational system only (Acute Procedural Success).
24 hours

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

Boston Scientific Corporation

수사관

  • 수석 연구원: Moussa Mansour,, MD, Massachusetts General Hospital

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 6월 3일

기본 완료 (추정된)

2027년 4월 1일

연구 완료 (추정된)

2028년 1월 1일

연구 등록 날짜

최초 제출

2024년 12월 11일

QC 기준을 충족하는 최초 제출

2024년 12월 13일

처음 게시됨 (실제)

2024년 12월 16일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 23일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 21일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

키워드

추가 관련 MeSH 약관

기타 연구 ID 번호

  • PF313

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

예

미국에서 제조되어 미국에서 수출되는 제품

예

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다